76319
document
Comparison of inhaled albuterol powder and aerosol in asthma . In this multicenter , randomized , double-blind study comparing the efficacy and safety of aerosolized albuterol with the dry powder formulation , 231 patients with chronic reversible obstructive airway disease were randomly allocated to receive either placebo albuterol aerosol followed immediately by active albuterol powder ( 200 micrograms ) or active albuterol aerosol ( two puffs , 180 micrograms ) followed immediately by placebo lactose powder four times a day for a period of 12 weeks . No statistically significant differences were found between the powder and aerosol formulations with respect to pulmonary function , length of time mean FEV1 remained greater than or equal to 15 % above baseline , physicians ' assessments of patients ' clinical response , or patients ' subjective symptom scores . There were also no significant differences between treatment groups in cardiovascular effects , laboratory values , or adverse events . Among patients who expressed a preference for one of the delivery systems , half preferred using the powder . Results of this study demonstrate that 200 micrograms of albuterol powder is as safe and effective as 180 micrograms of albuterol aerosol .
76320
Intervention_Pharmacological
inhaled albuterol powder and aerosol
76321
Intervention_Pharmacological
aerosolized albuterol with the dry powder formulation
76322
Intervention_Pharmacological
placebo albuterol aerosol
76323
Intervention_Pharmacological
active albuterol powder
76324
Intervention_Pharmacological
active albuterol aerosol
76325
Intervention_Pharmacological
placebo lactose powder
76326
Intervention_Pharmacological
powder
76327
Intervention_Pharmacological
aerosol
76328
Intervention_Pharmacological
albuterol powder
76329
Intervention_Pharmacological
albuterol aerosol
76330
Outcome_Physical
pulmonary function
76331
Outcome_Physical
length of time mean FEV1
76332
Outcome_Physical
physicians ' assessments of patients ' clinical response
76333
Outcome_Other
patients ' subjective symptom scores
76334
Outcome_Physical
cardiovascular effects
76335
Outcome_Physical
laboratory values
76336
Outcome_Adverse-effects
adverse events
76337
Outcome_Other
preference for one of the delivery systems
76338
Participant_Condition
asthma
76339
Participant_Sample-size
231
76340
Participant_Condition
chronic reversible obstructive airway disease
76341
Participant_Sample-size
half